Holen Sie sich die Stockscreener-App
33.84
0.30%
0.10
Handel nachbörslich:
33.63
-0.21
-0.62%
Schlusskurs vom Vortag:
$33.74
Offen:
$33.82
24-Stunden-Volumen:
2.63M
Relative Volume:
0.83
Marktkapitalisierung:
$6.43B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-14.04
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-0.97%
1M Leistung:
-0.03%
6M Leistung:
+42.66%
1J Leistung:
+9.02%
1-Tages-Spanne:
$33.57
$34.16
1-Wochen-Bereich:
$32.90
$36.11
52-Wochen-Spanne:
$21.62
$39.54
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
33.84 | 6.49B | 217.77M | -438.86M | -456.33M | -2.41 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Expands Team with 101,974 Shares in RSU Grants to 36 New Biotech Talents - Stock Titan
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance
Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com
Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - Yahoo Finance
BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus
BridgeBio launches landmark ATTR prevention study - Investing.com Australia
BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - Yahoo Finance
BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus
BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times
(BBIO) Trading Report - news.stocktradersdaily.com
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Recursion cuts nearly half of its pipeline - statnews.com
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales - insights.citeline.com
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio sales of new heart drug outstrip expectations - BioPharma Dive
BridgeBio (BBIO) Price Target Increased by Scotiabank Analyst | - GuruFocus
Attruby's Momentum and an Advancing Pipeline Support BridgeBio's Long-Term Growth Outlook - Morningstar
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Perf - GuruFocus
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Performance | BBIO Stock News - GuruFocus
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating - marketscreener.com
BridgeBio (BBIO) Price Target Uplifted by BofA Analyst Amid Stro - GuruFocus
Scotiabank raises BridgeBio stock target to $55 on strong sales By Investing.com - Investing.com India
Scotiabank raises BridgeBio stock target to $55 on strong sales - Investing.com
BridgeBio price target raised to $63 from $46 at Piper Sandler - TipRanks
BridgeBio (BBIO) Target Price Increased by Piper Sandler Followi - GuruFocus
BridgeBio (BBIO) Target Price Increased by Piper Sandler Following Strong Quarter | BBIO Stock News - GuruFocus
BridgeBio’s Attruby outperforms sales expectations, shares rise - Endpoints News
BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50 - TipRanks
(BBIO) Trading Advice - news.stocktradersdaily.com
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma: Q1 Earnings Snapshot - CT Insider
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):